[ad_1]
New anti-cancer drug targets DNA
Rather than the location of the tumor in the body
Thursday – 21 months Spring I 1440 H – 29 November 2018
The drug acts on mutagenic mutations (Reuters)
New York: The Middle East Online
The US Food and Drug Administration (FDA) has approved the introduction of a new anti-cancer drug after it has been tested on patients with lung, colon, breast, thyroid and other cancers. of other cancers, according to the American website.
The drug, developed by Loxo Oncology, acts on cancer mutations rather than cancer of the person and can treat cancer from its source and origin, in the adult and the child.
The company has set a low price of $ 132,000 a year for the fluid used to treat children. She also said she would provide financial assistance to patients to buy drugs, which would reduce the daily cost to $ 20 a month for most patients.
For his part, Scott Gottlieb, commissioner of the American Commission, said that "the ratification of this drug is an important step in the treatment of cancer, because it is treated at the source and treats the basis of cancerous tumors, whatever the location of the human body ".
He pointed out that the new drug will help cancer patients get proper treatment.
In 2017, the drug maker signed a $ 1.5 billion deal with Bayer, the cosmetics giant, and the development of two LUXO drugs, including Vitravi.
A genetic mutation is a new method of treating cancer. Is performed by most companies involved in the development of treatments for certain types of cancer, such as lung cancer or skin cancer, and requests approval of this type in the beginning, before performing additional tests to determine its effectiveness in combination with other types of cancer.
Scientists have observed genetic patterns across cancers for years, but the issue began to attract more attention in 2013 after the discovery that endometrial cancer is genetically similar to cancer forms of cancer. ovarian and breast cancer.
America
Cancer
[ad_2]
Source link
